Hypoxia-induced reactive oxygen species (ROS)-mediated expression of a variety of genes in endothelial cells has been suggested to be involved in abnormal cell adhesion.
Control of hypoxia-induced tumor cell adhesion by cytophilic human catalase

Introduction
Vascular endothelium is a monolayer lining the interior surface of blood vessels, which forms an interface between blood and tissue. Dynamically responding to changes in environmental factors, such as oxygen tension, cytokines and growth factors, endothelial cells play a pivotal role in maintaining physiological homeostasis [1] .
Abnormal cell adhesion to vascular endothelium is observed in a wide range of pathological situations, including arteriosclerosis, thrombosis and tumor metastasis [2] [3] [4] . Under these pathological conditions, local blood flow is impaired to induce microenvironmental changes that lead to the imbalance of oxygen demand and supply, and resulting hypoxia [5] . Endothelium that has experienced hypoxia can be the 'soil'
for tumor metastasis, because cells, including endothelial cells, increase the transcription of a variety of genes for adaptation to hypoxia [4] . An increasing body of evidence suggests that ROS play a central role in controlling hypoxia-induced transcription [6, 7] . Therefore, eliminating ROS in endothelial cells can be an efficient approach to controlling abnormal cell adhesion to endothelium. Catalase is an antioxidant enzyme that catalyzes the degradation of hydrogen peroxide, ROS with a long half-life. However, previous studies have demonstrated that catalase poorly interacts with cells [8] , so that any approaches to increasing its binding to cells could increase its therapeutic potential in a wide range of disease conditions.
A variety of molecules, including integrins and other adhesion molecules, are -4 - expressed on the surface of endothelial cells [9] . In addition, negative charge of cell surface provides a vast surface area for binding of cationic compounds [9] . In this study, two types of cytophilic human catalase (hCAT) derivatives were newly designed: one is hCAT fused with a arginine-glycine-aspartic acid (RGD) peptide, which is a well-known ligand for α v β 3 integrin, and the other is one fused with a nona arginine (R9) peptide, a cationic peptide. hCAT and its derivatives were expressed in P. pastoris, and their activity to inhibit hypoxia-induced tumor cell adhesion was examined.
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Materials and Methods
Cell culture
A mouse aortic vascular endothelial cell line (MAEC), a gift from Professor Ichiro Saito (Department of Pathology, Tsurumi University School of Dental Medicine, Yokohama, Japan), was cultured as previously reported [10] . B16-BL6/Luc [11] and colon26/Luc [12] , clones of murine melanoma B16-BL6 and murine colon carcinoma colon26 that stably express the firefly luciferase, were grown as reported previously. A murine Lewis lung cancer (LLC) was cultured as reported previously [13] . To establish LLC/Luc, LLC was transfected with pCMV-Luc [14] using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's instruction. Cell culture under hypoxic conditions (8 % oxygen) was carried out using an AnaeroPack (Mitsubishi Gas Chemical Co., Tokyo, Japan).
Expression and purification of recombinant human catalase derivatives
The pCMV6-Entry vector containing the genomic Homo sapiens catalase (NM_001752) cDNA was purchased from OriGene Technologies Inc. (Rockville, MD, USA).
Oligonucleotides corresponding to the amino acid sequence RGDRGDRGD (5'-AGAGGTGATAGAGGCGACAGAGGTGAC-3') or RRRRRRRRR (5'-AGAAGAAGGAGAAGAAGGAGAAGGAGA-3') were purchased from Greiner (1 % yeast extract, 2 % peptone, 2 % glucose) and grown at 30 °C in a bio-shaker with shaking at 250 rpm for 36 hr. A 2.5 mL aliquot of this suspension was inoculated to 500 mL of YPD medium in 3 L flask, and the culture was grown for 24 hr. The cells were harvested with 2000 ×g centrifugation, and disrupted using a French Press at 2,000 psi.
The clarified supernatants of cell lysates containing hCAT, hCAT-(RGD)3 or hCAT-R9
were loaded onto a glutathione sepharose column (GE Healthcare, U.K.), and these -7 - proteins were eluted by applying PreScission protease (GE Healthcare) in 50 mM
Tris-HCl solution (pH 7.5). After concentration by ultrafiltration, the solvent of each elute was changed to water. The purified catalase derivatives were stored at -20 °C until use.
Determination of catalase specific activity
Protein concentration was quantified using a BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Each catalase derivative (0.04 µg) was added to 25 mM phosphate buffer (pH 7.0) containing 10 mM hydrogen peroxide, and the decomposition of hydrogen peroxide was monitored spectrophotometrically at 240 nm. Samples were used without any separation of active (heme-containing) and inactive (heme free) forms. Bovine liver catalase (50,400 U/mg protein; Sigma Aldlich, USA) was used as a standard. Each sample was measured in five replicates and their averages were employed.
Measurement of circular dichroism
Circular dichroism (CD) spectra were recorded using a JASCO-820 type spectropolarimeter (JASCO, Tokyo, Japan) at 4 °C. For calculation of the mean residue ellipticity [θ], the molecular mass of the catalase derivatives was assumed to be as 240 kDa [8] . Far-UV (wavelength 200-250 nm) CD spectra were recorded at a protein concentration of 15 µM in Tris buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl).
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Interaction of catalase derivatives with endothelial cells
MAEC seeded on 24 well plates at a density of 1.0×10 5 cells/well were exposed to Medium 199 (Gibco, USA) containing one of the catalase derivatives at a concentration of 100 U/mL for 30 min at 4 °C or 37 °C. Then, the cells were washed with PBS and lysed with a lysis buffer (0.05 % Triton-X, 2 mM EDTA, 0.1 M Tris-HCl (pH 7.8)). The catalase activity of cell lysates was determined as described above.
Intracellular ROS production under hypoxic conditions
Intracellular ROS production was detected using CM-H 2 DCFDA (Invitrogen). MAEC
were treated with 5 μM CM-H 2 DCFDA for 1 hr, and then were cultured under hypoxic conditions of 8 % oxygen. The fluorescence intensity was measured using a 1420
Multilabel counter (PerkinEimer, USA) at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.
Measurement of luciferase activity
Cells were lysed with the lysis buffer. Twenty microliters of the lysate was mixed with 20 µL luciferase assay buffer (Picagene, Tokyo Ink, Tokyo, Japan) and the produced light was measured using a luminometer (Lumat LB 9507, EG&G Berthold, Bad
Wildbad, Germany).
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Cell adhesion assay
To examine the effect of hydrogen peroxide on tumor cell adhesion, MAEC ( The luciferase activity of the lysates was measured as described above. Separately, MAEC were incubated under normoxic or hypoxic conditions for 6 hr. Then, tumor cells were added and their adhesion was examined as above.
Transcription factor dependent reporter gene assay
MAEC seeded on 24 well plates at a density of 1. 
Statistical analysis
Differences were statistically evaluated by one-way ANOVA followed by the Tukey-Kramer multiple comparison test, and the level of statistical significance was set at P<0.05.
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Results
Characterization of catalase derivatives Figure 1 shows the schematic representation of human catalase derivatives: hCAT,
hCAT-(RGD)3 and hCAT-R9. Three constructs were expressed in P. pastoris, and purified as described in the Materials & Methods. Figure 2A shows the SDS-PAGE patterns of the human catalase derivatives. Each sample showed a single band of about 60 kDa, indicating that the catalase derivatives were adequately purified. The far-CD spectra of hCAT-(RGD)3 and hCAT-R9 were similar to that of hCAT ( Figure 2B ),
suggesting that the fusion of peptides hardly changed the secondary structure of human catalase. Figure 2C shows the time-dependent decomposition of hydrogen peroxide by the human catalase derivatives. The activities of hCAT, hCAT-(RGD)3 and hCAT-R9 ware 20,000, 19,500 and 24,300 units/mg protein, respectively, indicating that the fusion hardly reduced the specific activity of human catalase. These results are in a good agreement with the previous finding that the modification of C-terminus of catalase hardly influenced its activity [19] .
Next, the cellular association of catalase derivatives in MAEC was examined at 37 °C or 4 °C. The activity to degrade hydrogen peroxide in cellular fractions was 
Effect of catalase derivatives on intracellular ROS generation in MAEC under hypoxic conditions
The levels of intracellular ROS in MAEC were monitored using an ROS-sensitive probe.
The fluorescence intensity increased significantly at 3 to 9 hr after exposure to hypoxia 
Effect of catalase derivatives on transcription factor activity in MAEC under hypoxic conditions
To investigate the mechanism of inhibitory effect of catalase derivatives on hypoxia-induced cell adhesion, the activity of transcription factors HIF-1, NF-κB and AP-1 was estimated using pHRE-Luc, pNF-κB-Luc and pAP-1-Luc, respectively. The 
mRNA expression of adhesion molecules under hypoxic conditions
Finally, the changes in mRNA level of cell adhesion molecules that have reported to be -15 -induced by HIF-1 or NF-κB [20] were examined using RT-PCR. The expression of ICAM-1 was induced in MAEC under hypoxia (Figure 8 ), but that of VCAM-1 was hardly changed (data not shown). The increase in the mRNA level of ICAM-1 was reduced by all catalase derivatives examined.
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Discussion
Antioxidant enzymes including catalase have been believed to be promising therapeutic agents for a variety of human diseases related to oxidative stress, but the poor cell affinity of these enzymes has been a major obstacle in developing them as agents to protect cells and tissues from oxidative damage [8] . Recent studies have demonstrated that targeted or sustained delivery of bovine catalase by chemical modification is a therapeutic approach for ROS-mediated diseases, such as hepatic ischemia/reperfusion injury, cisplatin-induced nephrotoxicity and tumor metastasis [21] [22] [23] [24] . However, chemical modification of protein, in general, has some disadvantages, such as productivity and uniformity of the products, compared with genetic modification from a viewpoint of clinical application. Furthermore, heterologous proteins, such as bovine catalase, can be immunogenic, so that the use of human catalase instead of bovine origin will reduce the possibility of antibody production after administration to patients [25] .
In this study, we selected genetic engineering technique for modification of human catalase.
Previous studies have reported that enhanced delivery of biologically active proteins to cells is possible by using peptides that have high affinity with cells, including RGD peptide and oligoarginine peptide [26] [27] [28] . RGD motifs are found in many extracellular matrix proteins, and are recognized by and bound to integrins, a family of cell adhesion receptors expressed on the surface of various cells [29] . On the -17 -other hand, oligoarginine peptide is a short repeat of basic amino acid arginine, and it has been reported not only to bind to negatively charged cell membranes, but also to initiate macropinocytosis, a special form of endocytosis, which facilitates the internalization of surface-bound compounds [30] . In order to increase the affinity of catalase with endothelial cells, the C-terminus of catalase was fused with (RGD)3 peptide or R9 peptide. It has been reported that three repeat of RGD has higher affinity with integrins than monomeric RGD [29, 31] , so that the three repeat of the peptide was used for the construction of a catalase derivative containing RGD peptide. Both hCAT-(RGD)3 and hCAT-R9 showed an increased affinity for MAEC, but their cellular distribution was suggested to be different each other ( Figure 3) ; hCAT-(RGD)3 could be bound to cell surface, whereas a part of hCAT-R9 was considered to be internalized during the 30-min incubation. R9 peptide fused to C-terminus of catalase might initiate the active cellular uptake mechanism as suggested in a previous report [30] . Although cellular distribution of these two types of catalase derivatives can be different each other, In the design of catalase derivatives, the C-terminus of catalase was selected as the site for fusion with (RGD)3 peptide or R9 peptide. An X-ray structural analysis verified that the C-terminal region of human catalase is exposed on the surface of catalase molecule, and is distant from the active site [33] . In addition, human catalase contains a peroxisomal targeting signal in the C-terminal 11 amino acid sequence [16, 17] . These findings suggest that a peptide fused at the C-terminus is extended outside the protein, and is able to interact with integrins or negatively charged compounds on cell surface, which does not interfere with enzymatic activity of catalase. In fact, the activity and secondary structure of human catalase derivatives were not different from those of wild-type human catalase. These properties were quite contrast to those of chemically modified bovine catalase with an overall positive charge [22] . Administration of cytophilic catalase derivatives before or during surgical removal of primary tumors could reduce the incidence of tumor metastasis through the inhibition of tumor cell adhesion as observed in the present studies using cultured cells.
In conclusion, we have demonstrated that the fusion of (RGD)3 peptide or R9
peptide to the C-terminus of catalase is an efficient method of increasing the cytophilic activity of catalase. Both hCAT-(RGD)3 and hCAT-R9 efficiently inhibited hypoxia-induced cell adhesion through controlling intracellular oxidative stress in MAEC under hypoxic conditions. These results suggest that newly designed cytophilic human catalase derivatives can be effective therapeutic agents for controlling hypoxia-induced tumor cell adhesion.
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